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did not have thyroid or liver function test, respectively in
the previous 6 months. 
CONCLUSIONS: Patient safety from amiodarone toxic
effects is of high concern. Despite national guidelines and
a high prevalence of use, we found that over half of the
patients receiving amiodarone therapy were not being
monitored appropriately for toxicity. We conclude that
there is need for a formal amiodarone monitoring
program in this setting. We have designed and are testing
a chart reminder system to address this deﬁcit.
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OBJECTIVES: Clinical trials have demonstrated that
drug therapy can reduce osteoporosis-related fracture risk
in women over 50 years by up to 40% provided they 
consistently take their medication for a year or more.
Non-adherence with drug therapies not only limits the
drugs’ effectiveness, but could also be associated with a
higher fracture risk. The objective of this study was there-
fore to estimate fracture risk in relation to adherence with
osteoporosis medication in actual practice. 
METHODS: Demographic, prescription drug use, physi-
cian services and hospitalization information for females
with osteoporosis who were dispensed an osteoporosis
medication between 1996 and 2001 (entry date deﬁned
as ﬁrst dispensing in this period) was obtained from the
Saskatchewan Health data ﬁles. Adherence to treatment
was deﬁned as drug available to cover 80% of the time.
Subsequent fractures were identiﬁed via hospitalizations
or physician contacts with a relevant diagnostic or pro-
cedure code. The risk of fractures in relation to adherence
was examined using a Cox proportional hazards model
with time-dependent covariates. The impact of other
patient characteristics, including age, having suffered a
prior fracture, prior use of osteoporosis medication and
steroids, was also examined. 
RESULTS: 11,249 women suffering from osteoporosis
were identiﬁed with a mean age at the time of the index
prescription of 68.4 years and average follow-up of 2.3
years with a fracture rate of 4.5% per year. Patients 
who adhered experienced a 16% lower fracture rate. The
effect of adherence was maintained after controlling for
other patient characteristics that independently predict
the fracture rate, including interactions. 
CONCLUSIONS: These results indicate that improving
adherence in actual practice will signiﬁcantly decrease the
osteoporosis-related fracture risk.
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OBJECTIVES: To investigate under which circumstances
statins can be considered cost-effective in primary 
prevention of CHD, and to identify the most sensitive
parameters. 
METHODS: A Markov Model is used to tackle the
research question for the health insurance and the social
insurance in Germany. Life years gained are chosen as
effectiveness parameter. Mortality is based on the concept
of Gompertzian analysis, linking mortality rates for
persons with and without coronary heart disease (CHD).
Costs components comprise of prevention costs, costs in
the life years gained, national insurance contributions and
avoided costs for CHD-treatment. Age and gender spe-
ciﬁc costs and expenditures for health states are estimated
from data of the social insurance including pension 
payments. CHD-risk estimates are primarily based on
Framingham risk equations, but an alternative method
using current CHD-mortality data is used as well. 
RESULTS: With yearly Statin prices of 300 € (€/$ = .9)
and a relative CHD-risk reduction of 28%, statin treat-
ment for a 50 year old male with a yearly CHD-risk of
1,5% would cost between 23,000 € and 26,000 € per life
year gained for the social insurance and 13,000 € and
16,000 € for the health insurance. For higher CHD-risks
statin treatment gets more cost-effective. At a given value
of CHD-risk, cost-effectiveness is generally better for
younger patients. The most sensitive parameters are the
yearly statin prices und the relative risk reduction. Per 
rise in statin prices of 100 €, cost-effectiveness would
increase between 5,000 € and 7,000 € per life year gained
depending on age and gender. Avoided CHD-treatment
costs, however, have only a minor impact on the 
cost-effectiveness-ratio. 
CONCLUSIONS: Treatment guidelines for CHD preven-
tion incorporating cost-effectiveness considerations are
vulnerable to future statin pricing after the soon fall of
protection by patent. Correct risk estimation remains one
important objective in targeting resources for primary
CHD-prevention.
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The number needed to treat (NNT) has been promoted
as a tool for helping decision makers but valid compari-
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sons require correction of discrepancies among the trials
because differences in follow-up, comparator, endpoints
and population (i.e. reference risk) affect the NNT. 
OBJECTIVE: To examine use of the NNT to compare 
the medications for reducing cardiovascular risk that have
been introduced in the last decade and the modiﬁcations
required to ensure a balanced evaluation. 
METHODS: The literature from January 1, 1995 to
January 5, 2001 was comprehensively searched to iden-
tify relevant trials according to preset inclusion criteria.
The raw NNT (reciprocal of the rate difference) was cal-
culated using whatever data (event numbers, rates, rela-
tive risk, regression coefﬁcient) were extractable from the
papers. Differences in the populations studied, compara-
tor, length of follow-up and endpoints were addressed by
incorporating the data from each study in a model of car-
diovascular disease to derive a standardized NNT over
two years. 
RESULTS: 16 studies representing 22 therapeutic com-
parisons published since 1995 met the inclusion criteria.
The annual reference risk (in the control group) varied
from 2.4% to 14.8% and the follow-up time from 1 to
6.2 years. Only 2 studies used an active comparator.
Crude NNTs ranged from 9.2 for pravastatin (the older
subgroup in CARE) to 376 in quinapril (QUIET). The
corresponding standardized NNTs showed less variation
(10.3 to 85.5) and substantially changed the ranking of
therapies: clopidogrel’s (CAPRIE) NNT dropped 9-fold
and changed 13 places while trandolapril’s (TRACE)
increased 3-fold and went from second best to 16th. 
CONCLUSION: Despite advocacy by the evidence-based
medicine movement, crude NNTs cannot be used to
compare therapies as they reﬂect methodological dispar-
ities in the underlying trials. Using an NNT model allows
valid comparisons by standardizing the key parameters.
Doing so for cardiovascular therapies reveals much
smaller differences and considerably alters their ordering.
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OBJECTIVES: To compare the cost-effectiveness of the
vasodilator stress agents, adenosine and dipyridamole, in
subjects with known or suspected coronary artery disease
(CAD) undergoing technetium-99m sestamibi single
photon computed tomography (SPECT) imaging in a
prospective, randomized trial from a hospital perspective. 
METHODS: Direct medical costs (standardized to 2001
US dollars) of the vasodilator stress agents, adverse effects
and monitoring were included. To determine the 
effectiveness of adenosine and dipyridamole, the overall
accuracy of each agent was calculated as follows:
(number of true-positive results + number of true-
negative results)/(total number of tests), using cardiac
catheterization as the gold standard for comparison. 
The incremental cost-effectiveness ratio (ICER) was 
calculated as follows: (total cost of adenosine-total cost
of dipyridamole)/(overall accuracy of adenosine–overall
accuracy of dipyridamole). One-way sensitivity analysis
was conducted, varying the costs of adenosine, dipyri-
damole, adverse effects and monitoring. 
RESULTS: Baseline demographics, including gender, 
age, co-morbidities and number of diseased vessels were
similar between the groups (p > 0.05 for all comparisons).
With adenosine (n = 49) sensitivity, speciﬁcity and 
overall accuracy was 82% (32/39), 60% (6/10) and 78%
(38/49), respectively. The sensitivity, speciﬁcity and
overall accuracy for dipyridamole was 68% (34/50), 67%
(6/9) and 68% (40/59), respectively (p > 0.05 for all com-
parisons with adenosine). The incidence of adverse events
was 43% with adenosine and 12% with dipyridamole 
(p < 0.001). The mean cost of the vasodilator stress agent
was $154+/127 with adenosine and $10+/-2 with 
dipyridamole (p < 0.001). When the cost of adverse
effects and monitoring was included, the total cost rose
to $160+/-27 and $19+/-3 with adenosine and dipyri-
damole, respectively (p < 0.001). The ICER was $1,410
(sensitivity analysis: $1,390 – $1,676) for each additional
correctly identiﬁed case with adenosine. 
CONCLUSIONS: In a randomized trial of patients
referred for vasodilator stress using technetium-99m 
sestamibi SPECT imaging, data indicate that adenosine is
more expensive but more effective than dipyridamole in
CAD detection.
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OBJECTIVES: As pharmaceutical costs continue to esca-
late, formulary decisions for hospitals are emerging as a
key focus. We conducted a baseline analysis to determine
the current costs and clinical outcomes for patients who
undergo percutaneous transluminal coronary angioplasty
(PTCA) with Heparin at the Center, prior to implement-
ing a new anticoagulant, Bivalirudin. 
METHODS: Retrospective, observational, analysis of
patients discharged from the Washington Hospital Center
in 2000 undergoing PTCA. Inclusion criteria included all
patients who had an ICD-9 PTCA procedure code and 
a DRG PTCA code (112 or 116). There were approxi-
